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Bone marrow (BM)-derived endothelial progenitor cells (EPCs)
circulate in peripheral blood and play an important role in the
formation of new blood vessels (Asahara et al., 1997; Takahashi
et al., 1999; Zhou et al., 2013; Li et al., 2011). This process
occurs in response to a variety of growth factors, cytokines,
and chemokines, which cause EPCs to migrate towards target
tissues and differentiate into endothelial cells. Transplanta-
tion studies have revealed that EPCs incorporate into active
neovasculature in ischemic hind limbs and myocardium, and
growing tumors (Zhou et al., 2013; Otani et al., 2002; Kalka
et al., 2000). Number and migratory activity of circulating
EPCs have been reported to be inversely correlated with risk
factors for artery diseases, but directly correlated with
tumor growth and metastasis (Vasa et al., 2001; Naik et al.,
2008). Therefore, EPCs have been exploited for new inter-
vention strategies in therapeutic neovascularization (such as
ischemia) and certain angiogenesis-dependent diseases (such
as cancer) (Li Calzi et al., 2010).
An accumulating body of evidence indicates that the
chemokine receptor CXCR2 promotes neovascularization
and endothelial cell migration (Li et al., 2003; Schraufstatter
et al., 2001). CXCR2 is a G protein-coupled receptor that can
be activated by the ELR+ CXC chemokines, including CXCL1
(keratinocyte-derived chemokine; KC/murine CXCL1) and
CXCL2 (macrophage inflammatory protein-2, MIP-2/murine
CXCL2/3) (Olson and Ley, 2002). Recently, it has been reported
that CXCR2 receptor and its cognate ligands mediate EPC
recruitment and angiogenesis in injured endothelium (Hristov
et al., 2007), ischemic myocardium (Kocher et al., 2006),
and allergic airway disease (Jones et al., 2009; Imaoka et al.,
2011). Also, it has been shown thatmobilization of BM-derived
EPCs was attenuated in CXCR2 knockout mice with pancreatic
cancer (Li et al., 2011).
PDZ (PSD-95/DlgA/ZO-1) domains are modular protein
interaction domains that form peptide-binding clefts and
typically mediate interactions with the carboxyl termini of
other proteins that terminate in consensus binding motifs
(referred to as PDZ motif) (Li and Naren, 2010). A variety of
PDZ domain-containing proteins (also referred to as PDZ
scaffold or adaptor proteins) have been documented to
nucleate the formation of compartmentalized multiprotein
complexes critical for specific cell signaling (Li et al., 2005,
2007, 2010). Of note, both human and murine CXCR2 possess
a consensus PDZ motif at their carboxyl termini. We have
recently reported that the PDZ motif (TTL) of CXCR2 is
involved in the regulation of intracellular signaling and cellular
functions in neutrophils (Wu et al., 2012) and pancreatic
cancer cells (Wang et al., 2013).We showed that CXCR2 and its
downstream signaling molecule PLC-β are clustered by a
PDZ adaptor protein NHERF1 which scaffolds a CXCR2–
PLC-β complex through PDZ-mediated interactions (Wu et
al., 2012; Wang et al., 2013). We also reported the crystal
structure of the complex formation by X-ray crystallization,which provides the structural basis for CXCR2-mediated
cellular functions in neutrophils and pancreatic cancer cells
(Lu et al., 2013; Jiang et al., 2014). However, the putative role
and the molecular mechanisms that underlie the functional
significance of potential PDZ-based CXCR2 complexes in EPC
mobilization, homing, and incorporation into neovasculature
have not been determined. The objective of this study was
to define the biological role and molecular mechanisms of
the PDZ motif of CXCR2 in the regulation of EPC homing and
angiogenesis.
Materials and methods
Antibodies and reagents
Anti-human and mouse CXCR2 and PLC-β3 antibodies as well
as mouse anti-NHERF1 monoclonal antibody were purchased
from Santa Cruz Biotechnology. Rabbit anti-NHERF1 poly-
clonal antibody was bought from Sigma-Aldrich. Recombi-
nant chemokines, IL-8/CXCL8 and macrophage inflammatory
protein 2 (MIP-2/murine CXCL2/3) as well as growth factor
VEGF (both mouse and human) were obtained from ProSpec
(East Brunswick, NJ). Growth factor reduced Matrigel
matrix, glutathione agarose beads and Transwell inserts
were purchased from BD Bioscience. The human and murine
CXCR2 C-tail peptides (biotin-conjugate at N-terminus): WT
(biotin-FVGSSSGHTSTTL for human CXCR2 C-tail; and Biotin-
FVSSSSANTSTTL for mouse CXCR2 C-tail) and PDZ motif
deletion (ΔTTL) were synthesized by Genemed Synthesis,
Inc. (San Antonio, TX), and used as reported before (Wu et
al., 2012; Wang et al., 2013). SB225002 was purchased from
Tocris Bioscience. ChariotTM peptide/protein delivery re-
agent was purchased from Active Motif. Fura-2 was obtained
from Invitrogen. GST PDZ fusion proteins (GST-NHERF1,
NHERF2, or PDZK1) were purified using glutathione agarose
beads (BD Bioscience), eluted with 50 mM glutathione, and
used in pull-down assay as reported before (Wu et al., 2012;
Wang et al., 2013). C-terminal fragments of murine CXCR2
(last 45 amino acids; i.e. a.a. 315–359) were generated by
PCR cloning into pEGFP-C3 vector (Invitrogen). CXCR2C-tail PDZ
motif deletion (ΔTTL) was generated using the QuikChangeTM
Site-directed Mutagenesis kit (Agilent Technologies), and also
cloned into pEGFP vector for plasmid construction.
EPC isolation and culture
Mouse bone marrow (BM) cells were obtained by flushing
the tibias and femurs from C57BL/6J mice with PBS. The BM
mononuclear cells (MNCs) were isolated by density centrifu-
gation over Histopaque1083 (Sigma). The MNC layer was then
collected and counted. Eighty million cells were seeded over
one fibronectin (10 μg/ml) coated 60-mm Petri dish with
endothelial cell basal medium-2 (EBM-2) (Lonza) supplemented
with endothelial cell growthmedium-2 (EGM-2) MV SingleQuots
(Lonza) containing FBS (5%), vascular endothelial growth factor
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insulin-like growth factor 1, hydrocortisone, ascorbic acid and
antibiotics. After 3 days in culture, non-adherent cells were
removed, and culture mediumwas changed every 2 days. EPCs
were characterized by double staining with DiI-Ac-LDL and
BS-Lectin I, and flow cytometric analysis of specific EPC surface
markers (CD34 and VEGFR2) on day 7 as previously reported
(Chen et al., 2012). Mouse BM-derived EPCs were also obtained
from Celprogen. The EPCs have been characterized by the
Celprogen Company and are stained positive for CD34, CD45,
Sca-1 & AP, and demonstrate incorporation of acetylated LDL.
The cells were maintained in EBM-2 supplemented with EGM-2
MV SingleQuots, and sub-cultured every 2 days on murine
fibronectin-coated culture plates. The cells between passages
2–6 were used for the experiments.
Human cord blood (CB)-derived EPCs (AC133+ progenitor
cells) were isolated from the cord blood obtained from
volunteers under an Institutional Review Board-approved
protocol by the Henry Ford Health System. The cord blood
MNC population was generated by Ficoll gradient centrifuga-
tion and was enriched for AC133+ cells by immune-magnetic
positive selection using the MidiMACS system (Miltenyi Biotec,
Auburn CA) according to the manufacturer's protocol. Upon
isolation AC133+ cells were suspended in CellGro® Stem
Cell Growth Medium (SCGM) (CellGenix) supplemented with
40 ng/ml of stem cell factor, 40 ng/ml of FMS-like tyrosine
kinase 3 and 10 ng/ml of thrombopoietin (all from CellGenix),
as described before (Janic et al., 2010). Cells weremaintained
under these conditions as a suspension culture to expand for
up to 30 days with the cell concentration kept between
5 × 105–1 × 106 cells/ml. For cellular functional studies (such
as adhesion and migration), primary AC133+ CB-EPC cells were
first differentiated in EGM-2 media supplemented with 2% FBS
and 2 ng/ml of VEGF and plated in 6-well plate coated with
human fibronectin at a concentration of 2 × 105 cells/ml.
Cells were allowed to differentiate for 2 weeks. The media
were changed every 2–3 days, and the cells were monitored by
inverted phase contrast microscopy to evaluate the morpho-
logical changes during differentiation, as described before
(Janic et al., 2010).
Cell adhesion assay
CXCR2 C-tail peptides (WT and ΔTTL) were mixed with
ChariotTM peptide delivery reagent (Active Motif; total volume
of 400 μl) at 22 °C for 30 min as reported before (Wu et al.,
2012; Wang et al., 2013). The Chariot-peptide complex was
then incubated with EPCs at 37 °C for 1 h. The cells were then
trypsinized and counted. EPCs (1 × 104 per well) were seeded
on fibronectin coated 96-well plates, and incubated for 1 h at
37 °C in serum reduced (0.5% FBS) EBM-2 medium containing
MIP-2 (100 ng/ml). After the removal of non-adherent cells by
2 washes with PBS, adhesion was quantified in triplicate by
counting adherent cells in 3 randomly selected fields per well
using Higher Power Field (HPF) in an inverted microscopy
(VWR Vista Vision).
Cell migration assay
EPC migration was assayed using the Transwell system
(Corning or BD) with 6.5-mm diameter polycarbonate filters(8-μm pore size) as described before (Wu et al., 2012). Filter
membranes were coated with 0.1% gelatin in migration
medium (0.5% FBS in EBM-2) for 2 h at 37 °C before use. EPC
cells were delivered with CXCR2 peptides (WT and ΔTTL) as
described above before trypsinization. EPCs (1 × 105) in 100 μl
of migration medium were loaded in the upper chamber of
gelatin-coated Transwell, and 500 μl migration medium con-
tainingMIP-2 (100 ng/ml)was added in the lower chamber. The
Transwell was then returned to the 37 °C incubator for 3 h to
allow the EPCs to migrate. Thereafter, the remaining cells in
the upper chamber were removed by cotton swap. The
migrated cells were stained with Diff-Quick stain kit (IMEB,
San Marcos, CA), and stained adherent cells were counted in 3
randomly selected fields per well using HPF under an inverted
microscopy.EPC in vitro incorporation into endothelial tubule
structure
EPCs were delivered with CXCR2 peptides (WT and ΔTTL)
as described above and then labeled with Dil-Ac-LDL (red
fluorescence; Vector Laboratories) or Calcein AM (green
fluorescence, Invitrogen). The peptide-delivered and
fluorophore-labeled EPCs (2 × 103) were co-plated with
human dermal microvascular endothelial cells (HDMVECs;
1 × 104) in Matrigel (30 μl) coated 96-well round bot-
tomed plates and cultured in EBM-2 medium containing
MIP-2 (100 ng/ml) at 37 °C for 3 h. The incorporated and non-
incorporated EPCs were quantified using ImageJ software.
The percentage of incorporated EPCs was calculated and
plotted. The proportion of EPCs in tubule structures
was determined in 10 random fields under a fluorescence
microscopy.Murine Matrigel plug angiogenesis assay
EPCs were transfected with pEGFP-C3 vectors expressing
murine CXCR2 last 45 a.a., WT and PDZ motif deletion
(pEGFP-CXCR2 C-tail WT and pEGFP-CXCR2 C-tail ΔTTL) using
Lipofectamine 2000 reagent (Invitrogen). Stable expression of
the constructs inmurine EPCswas obtained usingG418 selection
and expression confirmed by fluorescent microscopy and
Western blotting (Supplementary Figs. S6A and B). Approxi-
mately 5 × 105 EPCs stably expressing CXCR2 C-tail constructs
or vector alone in 100 μl of PBS was admixed with 500 μl of
Matrigel containing 40 units/ml heparin and 200 ng/ml MIP-2.
The Matrigel containing EPC mixtures were implanted by a
single s.c injection into the mid-dorsal region of wild-type
C57BL6/J mice. The Matrigel plugs containing EPCs were
collected 10 days after injection and processed, and sections
were made for histological study (H&E staining and
anti-CD31 immuno-staining). Microvessel density (CD31+
cells) was quantified in multiple mice and compared
between groups. Image analyses of the areas of CD31+
blood vessels, vessel number, and length of vessel perimeter
were carried out as reported (Kong et al., 2007). All the animal
studies were accomplished under the protocol approved by
Wayne State University Institutional Animal Care and Use
Committee.
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EPCs (2 × 106/ml) were delivered with CXCR2 C-tail peptides
(WT or ΔTTL) as described above, and then labeled with
5 μM Fura-2 AM in HBSS buffer at 37 °C for 45 min. The
fluorescence of cell suspensions was continuously monitored
in a PTI fluorescence spectrophotometer at excitation
wavelengths of 340 nm and 380 nm, and emission wave-
length of 510 nm as reported before (Wu et al., 2012). MIP-2
(100 ng/ml) was added once the baseline was stabilized, and
ionomycin (5 μM, a calcium-specific ionophore) and EGTA
(10 mM) were added towards the end of experiments. The
intracellular calcium levels (in nM) were calculated as
described previously (Wu et al., 2012).
Pull-down assay
GST pull-down assay was performed as previously described
(Wu et al., 2012; Wang et al., 2013). Briefly, fresh EPCs were
lysed in binding buffer (PBS + 0.2% Triton X-100) supplement-
ed with a mixture of protease inhibitors (containing 1 mM
phenylmethylsulfonyl fluoride, 1 μg/ml aprotinin, 1 μg/ml
leupeptin, and 1 μg/ml pepstatin) and phosphatase inhibitor
mixture (Sigma). The cleared supernatant (17,000 ×g, 15 min)
was equally mixed with GST alone or various GST-PDZ fusion
proteins (GST-NHERF1, GST-NHERF2, or GST-PDZK1) at 4 °C
for 2 h. The mixture was further incubated with glutathione
agarose beads at 4 °C overnight, washed three times with
binding buffer, and eluted in Laemmli sample buffer contain-
ing β-mercaptoethanol. The eluents were separated by
SDS-PAGE and immunoblotted with anti-CXCR2 antibody.
Co-immunoprecipitation
A co-immunoprecipitation kit (Thermo Scientific/Pierce) was
used to immobilize the normal IgG control and anti-CXCR2 IgG
to the resin according to manufacturer's instruction. EPCs were
lysed in binding buffer (PBS + 0.2% Triton X-100 + protease
inhibitors), and cleared cell lysates (17,000 ×g, 15 min) were
processed for co-immunoprecipitation as reported before (Wu
et al., 2012; Wang et al., 2013). The co-precipitated protein
complex was resolved by SDS-PAGE, and probed for NHERF1 and
PLC-β3. The signal was detected by SuperSignal® West Pico (or
Femto) substrate (Thermo Scientific).
Results
EPC isolation and characterization
In the present study, we used EPCs from multiple sources. In
addition to using murine EPCs from a commercial source
(Celprogen Company), we also isolated and cultured murine
EPCs in our laboratory according to previously reported
protocols (Ii, 2010; Tepper et al., 2005). These cultured cells
adhered gradually and displayed spindle-shaped morphology
(Fig. 1A), similar to that of EPCs originally reported by Asahara
et al. (1997). The identity of these cells as EPCs was confirmed
by up-taking of DiI-Ac-LDL and staining with FITC-conjugated
BS-Lectin I (Fig. 1B). We also used EPCs isolated from human
cord blood in the study, which were cultured and expanded in
vitro as reported previously (Janic et al., 2010) (Fig. 1C).CXCR2 signaling mediates the migratory and
angiogenic activities of EPCs
Using mouse EPCs isolated from bone marrow, we examined
the effects of CXCR2 blockade on EPC migration, adhesion,
invasion, and incorporation into endothelial tubule struc-
ture in vitro. EPCs obtained from the Celprogen Company
were also investigated in these cell-based assays. We
observed that MIP-2 (the murine CXCL2/3), IL-8/CXCL8,
and murine VEGF all significantly increased mouse EPC
migration through gelatin, adhesion to fibronectin matrix,
invasion through Matrigel, and in vitro incorporation into
endothelial tubule network (Supplementary Figs. S1–4).
However, a goat anti-murine CXCR2 neutralizing antibody
(Farooq et al., 2009) and a selective non-peptide CXCR2
antagonist SB225002 (White et al., 1998) significantly inhibited
EPC cellular functions when induced by MIP-2 and IL-8, but not
by VEGF (Supplementary Figs. S1–4). These observations are
consistentwith the findings of others (Hristov et al., 2007; Jones
et al., 2009).
In order to confirm that the results were not only
restricted to murine EPCs, we tested the migratory and
angiogenic capacities of human EPCs. The human EPCs were
isolated from the cord blood and have been previously
characterized by us and other investigators (Janic et al., 2010,
2012; Arbab et al., 2006; Silverman et al., 2007). Similar results
were observed with human EPCs where CXCR2 regulates EPC
migratory and angiogenic activities in vitro (Supplementary
Fig. S5).Disrupting CXCR2 PDZ motif-mediated interactions
inhibits EPC in vitro adhesion and migration
The PDZ motif (TTL) of CXCR2 has been reported to be involved
in modulating cellular chemotaxis in CXCR2-overexpressed
HEK293 cells (Baugher and Richmond, 2008). We recently
showed that this motif regulates intracellular signaling and
cellular functions in both neutrophils (Wu et al., 2012) and
pancreatic cancer cells (Wang et al., 2013). As CXCR2 plays an
essential role in EPC homing and angiogenesis (Hristov et al.,
2007; Jones et al., 2009), it is important to seewhether this PDZ
motif is also involved in CXCR2-mediated EPC homing and
angiogenesis. To elucidate the potential role of the PDZmotif in
CXCR2-mediated EPC motility, we delivered a murine CXCR2
C-tail peptide containing the PDZmotif (Biotin-FVSSSSANTSTTL;
WT) and a PDZ motif deletion peptide (Biotin-FVSSSSANTS;
ΔTTL) into murine EPCs. We observed that EPC adhesion to
fibronectin stimulated by MIP-2 was significantly inhibited
by the pre-treatment of the C-tail WT peptide, but not
significantly altered by the ΔTTL peptide (Fig. 2A). Similar
inhibitory effects by the WT peptide were also observed in
EPC migration (Fig. 2B), whereas the ΔTTL peptide pre-
treatment did not elicit any significant inhibition in the
migration.
We also delivered human CXCR2 C-tail peptides (WT and
ΔTTL peptides, as reported previously (Wu et al., 2012; Wang
et al., 2013)) into human EPCs isolated from cord blood, and
then assessed EPC adhesion and migration stimulated by IL-8
(human CXCL8). We observed similar inhibitory effects of the
WT peptide pre-treatment on both EPC adhesive andmigratory
activities (Fig. 3).
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Merge (4X) Phase-contrast (4X)
Day 1 (4x) Day 7 (10x) Day 14 (10x)A
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Figure 1 EPC culture and characterization. (A) Morphology (phase-contrast images, 4× or 10× objective) of mouse bone
marrow-derived EPCs (BM-EPCs) in culture at various time intervals. (B) Cultured BM-EPCs stained with DiI-Ac-LDL (red), BS-Lectin I
(green), DAPI (blue). A phase contrast image was also shown. (C) Morphology (phase-contrast images, 10× objective) of human cord
blood-derived EPCs (CB-EPCs) in culture at various time intervals. Differentiation potential of primary long term AC133+ CB-EPCs
was evaluated at day 14 and day 28 of in vitro expansion (see Materials and methods for details).
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blocks EPC in vitro incorporation into endothelial
tubule structure
Previous studies suggested that EPCs work in concert with
existing endothelial cells to form vessels, but not entirely new
vessels de novo (Tepper et al., 2002). A recent study reported
that a neutralizing CXCR2 monoclonal antibody significantly
reduced the incorporation of human EPCs at the sites of injury
in the carotid arteries of athymic nude mice (Hristov et al.,
2007). To evaluate EPC incorporation into endothelial tubule
network, Dil-Ac-LDL-labeled EPCs were co-cultured withhuman dermal microvascular endothelial cells (HDMVECs) in
Matrigel. MIP-2 and VEGF enhanced EPC incorporation into the
endothelial cell tubule structure (Supplementary Fig. S4).
However, EPC incorporation induced byMIP-2was significantly
inhibited by the pretreatment of EPCs with the CXCR2 C-tail
WT peptide, but not with the ΔTTL peptide (Fig. 4).
Disrupting CXCR2 PDZ motif-mediated interactions
decreases EPC in vivo angiogenesis in mice
EPCs have been shown to home to sites of neovascularization,
differentiate intomature endothelial cells and incorporate into
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Figure 2 Disrupting CXCR2 PDZ motif-mediated interactions inhibits in vitro adhesion and migration of mouse BM-EPCs. (A) Mouse
BM-EPC adhesion to fibronectin in response to MIP-2 (100 ng/ml) pre-delivered with ChariotTM peptide delivery reagent only or along
with mouse CXCR2 C-tail peptides (WT — wild type, ΔTTL — PDZ motif deletion), as shown in the representative pictures (top) and bar
graphs (bottom). *P b 0.05 compared to the control (n = 4). (B) EPC migration across gelatin-coated Transwell in response to MIP-2
(100 ng/ml) pre-delivered with CXCR2 C-tail peptides, as shown in the representative pictures (top) and bar graphs (bottom).
*P b 0.05 compared to the control (n = 4).
138 Y. Hou et al.the microvasculature in situ (Nolan et al., 2007; Vajkoczy et
al., 2003). To evaluate the functional significance of the CXCR2
PDZ motif in EPC neovascularization in vivo, we performed an
EPC Matrigel plug assay to induce in vivo angiogenesis in mice.
CXCR2 C-tail DNA constructs containing the murine CXCR2 last
45 a.a. (WT and PDZ motif deletion) were engineered into the
pEGFP-C3 vector (pEGFP-CXCR2 C-tail WT and pEGFP-CXCR2C-tail ΔTTL). Stable expression of the constructs in murine
EPCs was obtained using G418 selection and expression
confirmed by fluorescent microscopy and Western blotting
(Supplementary Figs. S6A and S6B). EPCs stably expressing
the CXCR2 C-tail constructs were implanted subcutaneously
with the Matrigel supplemented with MIP-2 in C57BL/6J
mice. After 10 days, the mice were sacrificed and the gels
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Figure 3 Disrupting CXCR2 PDZ motif-mediated interactions inhibits in vitro adhesion and migration of human CB-EPCs. EPC
adhesion (A) and migration (B), in response to IL-8 (100 ng/ml) pre-delivered with human CXCR2 C-tail peptides (WT or ΔTTL), were
performed similarly as in Fig. 2.
139A critical role of CXCR2 PDZ-mediated interactions in endothelial progenitor cell homing and angiogenesiswere recovered for analysis. Visually, there were fewer blood
vessels formed in the Matrigel containing EPCs transfected
with pEGFP-CXCR2 C-tail WT as compared with Matrigel
containing EPCs transfected with pEGFP-CXCR2 C-tail ΔTTL.
Histology of the Matrigel plug from the WT group revealed
smaller and fewer blood vessel formation (arrows) than the
ΔTTL group (Fig. 5A), and also fewer CD31 positive blood
vessels (Fig. 5B). Microvessel density (CD31+ cells) was
quantified and compared between groups. The Matrigel
plug from the WT group showed significantly reduced vessel
number relative to the ΔTTL group (Fig. 5C). Western blot
analysis of the homogenates from the plug tissues demon-
strated that the transfected constructs were expressed in
the plug tissues (Fig. 5D), confirming the success of stable
gene expression in EPCs.*
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Figure 4 Disrupting CXCR2 PDZ motif-mediated interactions
blocks EPC in vitro incorporation into endothelial tubule struc-
ture. EPC in vitro incorporation into HDMVEC tubule structure in
response to MIP-2 (100 ng/ml) pre-delivered with CXCR2 C-tail
peptides (WT or ΔTTL). The percentage of incorporated EPCs was
calculated and plotted. *P b 0.05 compared to the control (n = 3).Disrupting CXCR2 PDZ motif-mediated interactions
reduces CXCR2-mediated EPC intracellular calcium
mobilization
CXCR2 couples to the pertussis toxin-sensitive Gi proteins to
stimulate phosphatidylinositide-specific phospholipase C
(PLC) activities (Wu et al., 1993). Agonist-induced activation
of PLC-β, one of the six families of PLC isozymes, catalyzes the
hydrolysis of phosphatidylinositol 4,5-bisphosphate, generat-
ing 1,2-diacylglycerol and inositol-1,4,5-trisphosphate (IP3),
which then activates PKC isoforms and triggers the release
of Ca2+ from internal sources, respectively. One of the
important intracellular events triggered by CXCR2 activa-
tion is the cytosolic calcium mobilization, which is due to
both IP3-mediated intracellular calcium release and an
influx of extracellular calcium (Rah et al., 2005). Calcium
signaling has been reported to play an essential role in the
mobilization and recruitment of EPCs to the sites of vascular
remodeling and neovascularization (Maeng et al., 2009). We
next wanted to see whether disrupting CXCR2 PDZ-mediated
interactions would attenuate CXCR2 ligand-induced EPC
intracellular calcium mobilization that eventually leads
to EPC homing (mobilization and recruitment). Our results
demonstrated that calcium mobilization in EPCs induced by
MIP-2 was significantly inhibited by the pretreatment of EPCs
with the CXCR2 C-tail WT peptide, but not with the CXCR2
C-tail ΔTTL peptide (Fig. 6).
CXCR2 interacts with relevant signaling proteins via
PDZ-based interactions
Using a PDZ array (Panomics) and GST pull-down assay, we
have recently identified several PDZ scaffold proteins that
interact with the CXCR2 C-tail containing the PDZ motif (Wu
et al., 2012). Among them are NHERF1 and NHERF2 which are
also expressed in EPCs (data not shown). Here we demon-
strated that NHERF1 pulled down endogenous CXCR2 from
EPCs, while NHERF2 and PDZK1 failed to do so (Fig. 7A). This
suggests that endogenous CXCR2 in EPCs interacts preferen-
tially with NHERF1.
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Figure 5 Perturbing CXCR2 PDZ-mediated interactions in-
hibits EPC in vivo neovascularization. (A) Histology of Matrigel
plug implanted with EPCs expressing pEGFP-CXCR2 C-tail WT
(left) and C-tail ΔTTL (right); Arrows indicate locations of blood
vessel formation. (B) Immunohistochemical (IHC) detection of
CD31 in Matrigel plug with pEGFP-CXCR2 C-tail WT (left) and
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EPCs stably expressing pEGFP-CXCR2 C-tail (WT and ΔTTL).
140 Y. Hou et al.It was reported that knockdown of PLC-β2 in EPCs led
to marked reduction in EPC adhesion and intracellular
calcium mobilization stimulated by the insulin-like growthfactor 2 receptor (Maeng et al., 2009). As shown in Fig. 6,
perturbing the CXCR2 PDZ-based interactions using the
CXCR2 WT peptide inhibited the CXCR2-mediated intracel-
lular calcium signal in EPCs. Based on these observations,
we wanted to know which PLC-β isoform(s) might interact
with CXCR2 in EPCs. Towards this end, we performed
co-immunoprecipitation experiments using CXCR2 antibody.
We found that, in addition to NHERF1 (Fig. 7B), PLC-β3 in EPCs
was also co-immunoprecipitated with CXCR2 (Fig. 7C). Since
PLC-β3 also possesses a PDZ-binding motif at its C-terminus
(Wang et al., 2013), it is reasonable to speculate that CXCR2
may interact indirectly with PLC-β3 and this interaction may
be mediated by PDZ adaptor protein NHERF1 that clusters
CXCR2 and PLC-β3 into a spatially-compact multi-protein
signaling complex for specific and efficient signaling in EPCs.
DiscussionA large body of evidence has accumulated to indicate that
EPCs, a subpopulation of vascular precursor cells in the
blood, have the capacity to migrate, proliferate, and differen-
tiate into mature endothelial cells in a variety of systems.
EPCs contribute to postnatal neovascularization and play
important roles in both ischemic vascular repair and tumor
growth (Asahara et al., 1997; Bagley et al., 2003). The
homing of EPCs to neovascular areas requires a coordinated
sequence of multistep events, including chemoattraction,
adhesion, and invasion, before incorporation and differentia-
tion into endothelial cells (Vajkoczy et al., 2003). A number of
locally produced factors, including cytokines, chemokines, and
growth factors, are involved in orchestrating these processes.
Several key angiogenic chemokines (CXCL1, CXCL2, CXCL7,
CXCL8, CXCL12) and their cognate receptors (CXCR2, CXCR4)
have been reported to regulate EPC mobilization, recruitment,
and firm adhesion during EPC homing to the sites of arterial
injury (Hristov et al., 2007; Kocher et al., 2006; Jones et al.,
2009; Imaoka et al., 2011; Chen et al., 2012; Cheng et al.,
2010). Although the role of EPCs in supporting postnatal
neovascularization is under intensive investigation, the
mechanisms and factors regulating these signaling events
are still not fully understood.
In the present study, our data generated from the
biochemical assays (Fig. 7) and functional studies (Figs. 2–5)
indicated that the C-terminal PDZ motif of CXCR2 is important
for EPC motility and angiogenic activity both in vitro and in
vivo. Our findings suggested that a PDZ-based CXCR2 macro-
molecular complex might regulate EPC function during
postnatal neovascularization (Fig. 5) as well as its incorpora-
tion into endothelial tubule structure (Fig. 4). Growing
evidence suggested that PDZ scaffold/adaptor proteins, such
as NHERF1, NHERF2, and PDZK1, nucleate the formation of
compartmentalized multiprotein complexes that are critical
to specific cellular signaling (Li et al., 2005, 2007, 2010; Naren
et al., 2003). These PDZ adaptor proteins provide scaffolds for
localization and organization of membrane receptors or ion
channels and downstream effectors to be close to each other,
leading to efficient signaling transduction. It was previously
reported that EPC adhesion to activated endothelium was
selectively inhibited by the antiserum directed against the
PDZ motif of a cell adhesion molecule, shCD146, suggesting
that this PDZ motif is involved in the EPC adhesion process
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Figure 7 CXCR2 interacts with relevant signaling proteins via
PDZ–based interactions. (A) Endogenous CXCR2 in EPCs was pulled
down by PDZ proteins, and immunoblotted with anti-murine
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141A critical role of CXCR2 PDZ-mediated interactions in endothelial progenitor cell homing and angiogenesis(Kebir et al., 2010). We have recently shown that the
NHERF1-scaffolded CXCR2–PLC-β complexes regulate CXCR2
signaling in neutrophils and pancreatic cancer cells (Wu et al.,
2012; Wang et al., 2013). We also demonstrated the direct
interaction betweenNHERF1 and CXCR2 aswell as NHERF1 and
PLC-β3 in the crystal structure studies (Lu et al., 2013; Jiang
et al., 2013, 2014). It is therefore conceivable that CXCR2
could also mediate potential interaction with certain PDZ
scaffold proteins in EPCs. This interaction might conse-
quently cluster CXCR2 with other relevant signaling mole-
cules into multiprotein macromolecular signaling complexes.
It is important to note that the present study suggested the
presence of an NHERF1-mediated CXCR2–PLC-β3 complex
in EPCs (Fig. 7), implying a functional significance of this
complex in EPC mobilization, homing, and incorporation into
neovasculature.
Finally, the present study suggested that targeting the
PDZ-based CXCR2 complex might be an effective strategy
for therapeutic intervention of angiogenesis-dependent
diseases. EPCs participate in pathologic angiogenesis and
contribute to tumor growth and airway remodeling in
asthma (Jones et al., 2009; Imaoka et al., 2011; Goon et
al., 2006; Yeager et al., 2011). Inhibiting EPC angiogenic
activity might thus represent a promising approach to
restrict vessel growth in those pathological conditions. We
showed that blocking the PDZ-mediated CXCR2–NHERF1
interaction is sufficient to inhibit EPC angiogenic activity
resulting in significantly reduced vessel density in the
mouse Matrigel plug assay (Fig. 5). This result suggested
that targeting this PDZ interaction might have therapeutic
applications in the EPC-associated diseases. Recent findings
supported the idea that PDZ domains might indeed be
valuable drug targets. Blocking the PDZ interaction be-
tween the NMDA glutamate receptor and PSD-95 has been
shown to result in selective inhibition of neuronal nitric oxide
synthase activation, which is expected to reduce ischemicbrain injury during stroke (Aarts et al., 2002). Recent evidence
suggested that blocking the PDZ domains of NHERF1 might be
an interesting therapeutic approach to inhibit tumorigenesis
associated with breast cancer (Dai et al., 2004). In addition,
the PDZ domain of PICK1, which binds the C terminus of
AMPA-type ionotropic glutamate receptors, has recently
been recognized as a putative target in the treatment of
neuropathic pain, excitotoxicity, and cocaine addiction
(Bell et al., 2009; Bellone and Luscher, 2006). Therefore,
targeting the PDZ-based CXCR2 complex in EPCs could prove
valuable in therapeutic intervention of pathologic angio-
genesis (such as tumor angiogenesis).Acknowledgments
This work was supported by the Elsa U. Pardee Foundation
research grant, an American Heart Association grant
#0765185B, the Wayne State University Cardiovascular Re-
search Institute Isis Initiative award, and American Cancer
Society Institutional Research Grant #11-053-01-IRG (to C.L.),
and the Leukemia Research Foundation, Aplastic Anemia and
MDS International Foundation, and American Heart Associa-
tion grant number 0835085N (to Z.Y.).
142 Y. Hou et al.Appendix A. Supplementary data
Supplementary data to this article can be found online at
http://dx.doi.org/10.1016/j.scr.2014.12.001.References
Aarts, M., et al., 2002. Treatment of ischemic brain damage by
perturbing NMDA receptor—PSD-95 protein interactions. Science
298 (5594), 846–850.
Arbab, A.S., et al., 2006. Magnetic resonance imaging and confocal
microscopy studies of magnetically labeled endothelial progenitor
cells trafficking to sites of tumor angiogenesis. Stem Cells 24 (3),
671–678.
Asahara, T., et al., 1997. Isolation of putative progenitor endothe-
lial cells for angiogenesis. Science 275 (5302), 964–967.
Bagley, R.G., et al., 2003. Endothelial precursor cells as a model of
tumor endothelium: characterization and comparison with
mature endothelial cells. Cancer Res. 63 (18), 5866–5873.
Baugher, P.J., Richmond, A., 2008. The carboxyl-terminal PDZ
ligand motif of chemokine receptor CXCR2 modulates post-
endocytic sorting and cellular chemotaxis. J. Biol. Chem. 283
(45), 30868–30878.
Bell, J.D., et al., 2009. PICK1-mediated GluR2 endocytosis contrib-
utes to cellular injury after neuronal trauma. Cell Death Differ.
16 (12), 1665–1680.
Bellone, C., Luscher, C., 2006. Cocaine triggered AMPA receptor
redistribution is reversed in vivo by mGluR-dependent long-term
depression. Nat. Neurosci. 9 (5), 636–641.
Chen, J., et al., 2012. Transfusion of CXCR4-primed endothelial
progenitor cells reduces cerebral ischemic damage and promotes
repair in db/db diabetic mice. PLoS ONE 7 (11), e50105.
Cheng, M., et al., 2010. CXCR4-mediated bone marrow progenitor
cell maintenance andmobilization are modulated by c-kit activity.
Circ. Res. 107 (9), 1083–1093.
Dai, J.L., et al., 2004. NHERF (Na+/H+ exchanger regulatory factor)
gene mutations in human breast cancer. Oncogene 23 (53),
8681–8687.
Farooq, S.M., et al., 2009. Therapeutic effect of blocking CXCR2 on
neutrophil recruitment and dextran sodium sulfate-induced
colitis. J. Pharmacol. Exp. Ther. 329 (1), 123–129.
Goon, P.K., et al., 2006. Circulating endothelial cells, endothelial
progenitor cells, and endothelial microparticles in cancer.
Neoplasia 8 (2), 79–88.
Hristov, M., et al., 2007. Importance of CXC chemokine receptor 2 in
the homing of human peripheral blood endothelial progenitor
cells to sites of arterial injury. Circ. Res. 100 (4), 590–597.
Ii, M., 2010. Bone marrow-derived endothelial progenitor cells:
isolation and characterization for myocardial repair. Methods
Mol. Biol. 660, 9–27.
Imaoka, H., et al., 2011. Lung homing of endothelial progenitor cells
in humans with asthma after allergen challenge. Am. J. Respir.
Crit. Care Med. 184 (7), 771–778.
Janic, B., et al., 2010. Human cord blood-derived AC133+ progenitor
cells preserve endothelial progenitor characteristics after long
term in vitro expansion. PLoS ONE 5 (2), e9173.
Janic, B., et al., 2012. MRI tracking of FePro labeled fresh and
cryopreserved long term in vitro expanded human cord blood
AC133+ endothelial progenitor cells in rat glioma. PLoS ONE 7
(5), e37577.
Jiang, Y., et al., 2013. New conformational state of NHERF1-CXCR2
signaling complex captured by crystal lattice trapping. PLoS ONE
8 (12), e81904.
Jiang, Y., et al., 2014. Crystallographic analysis of NHERF1-PLCbeta3
interaction provides structural basis for CXCR2 signaling in pancre-
atic cancer. Biochem. Biophys. Res. Commun. 446 (2), 638–643.Jones, C.P., et al., 2009. CXCR2 mediates the recruitment of
endothelial progenitor cells during allergic airways remodeling.
Stem Cells 27 (12), 3074–3081.
Kalka, C., et al., 2000. Transplantation of ex vivo expanded
endothelial progenitor cells for therapeutic neovascularization.
Proc. Natl. Acad. Sci. U. S. A. 97 (7), 3422–3427.
Kebir, A., et al., 2010. CD146 short isoform increases the proangiogenic
potential of endothelial progenitor cells in vitro and in vivo. Circ.
Res. 107 (1), 66–75.
Kocher, A.A., et al., 2006. Myocardial homing and neovasculariza-
tion by human bone marrow angioblasts is regulated by IL-8/Gro
CXC chemokines. J. Mol. Cell. Cardiol. 40 (4), 455–464.
Kong, D., et al., 2007. Inhibition of angiogenesis and invasion by
3,3′-diindolylmethane is mediated by the nuclear factor-kappaB
downstream target genes MMP-9 and uPA that regulated
bioavailability of vascular endothelial growth factor in prostate
cancer. Cancer Res. 67 (7), 3310–3319.
Li Calzi, S., et al., 2010. EPCs and pathological angiogenesis: when
good cells go bad. Microvasc. Res. 79 (3), 207–216.
Li, C., Naren, A.P., 2010. CFTR chloride channel in the apical
compartments: spatiotemporal coupling to its interacting part-
ners. Integr. Biol. 2 (4), 161–177.
Li, A., et al., 2003. IL-8 directly enhanced endothelial cell survival,
proliferation, and matrix metalloproteinases production and
regulated angiogenesis. J. Immunol. 170 (6), 3369–3376.
Li, C., et al., 2005. Lysophosphatidic acid inhibits cholera toxin-
induced secretory diarrhea through CFTR-dependent protein
interactions. J. Exp. Med. 202 (7), 975–986.
Li, C., et al., 2007. Spatiotemporal coupling of cAMP transporter to
CFTR chloride channel function in the gut epithelia. Cell 131 (5),
940–951.
Li, C., Schuetz, J.D., Naren, A.P., 2010. Tobacco carcinogen NNK
transporter MRP2 regulates CFTR function in lung epithelia:
implications for lung cancer. Cancer Lett. 292 (2), 246–253.
Li, A., et al., 2011. CXCR2-dependent endothelial progenitor cell
mobilization in pancreatic cancer growth. Transl. Oncol. 4 (1),
20–28.
Lu, G., et al., 2013. Structural insights into neutrophilic migration
revealed by the crystal structure of the chemokine receptor
CXCR2 in complex with the first PDZ domain of NHERF1. PLoS
ONE 8 (10), e76219.
Maeng, Y.S., et al., 2009. Endothelial progenitor cell homing: prominent
role of the IGF2-IGF2R-PLCbeta2 axis. Blood 113 (1), 233–243.
Naik, R.P., et al., 2008. Circulating endothelial progenitor cells
correlate to stage in patients with invasive breast cancer. Breast
Cancer Res. Treat. 107 (1), 133–138.
Naren, A.P., et al., 2003. A macromolecular complex of beta 2
adrenergic receptor, CFTR, and ezrin/radixin/moesin-binding
phosphoprotein 50 is regulated by PKA. Proc. Natl. Acad. Sci. U. S. A.
100 (1), 342–346.
Nolan, D.J., et al., 2007. Bone marrow-derived endothelial progenitor
cells are a major determinant of nascent tumor neovasculariza-
tion. Genes Dev. 21 (12), 1546–1558.
Olson, T.S., Ley, K., 2002. Chemokines and chemokine receptors in
leukocyte trafficking. Am. J. Physiol. Regul. Integr. Comp. Physiol.
283 (1), R7–28.
Otani, A., et al., 2002. Bone marrow-derived stem cells target
retinal astrocytes and can promote or inhibit retinal angiogen-
esis. Nat. Med. 8 (9), 1004–1010.
Rah, S.Y., et al., 2005. Activation of CD38 by interleukin-8 signaling
regulates intracellular Ca2+ level and motility of lymphokine-
activated killer cells. J. Biol. Chem. 280 (4), 2888–2895.
Schraufstatter, I.U., Chung, J., Burger, M., 2001. IL-8 activates
endothelial cell CXCR1 and CXCR2 through Rho and Rac signaling
pathways. Am. J. Physiol. Lung Cell. Mol. Physiol. 280 (6),
L1094–L1103.
Silverman, M.D., et al., 2007. The role of vascular cell adhesion
molecule 1/ very late activation antigen 4 in endothelial
143A critical role of CXCR2 PDZ-mediated interactions in endothelial progenitor cell homing and angiogenesisprogenitor cell recruitment to rheumatoid arthritis synovium.
Arthritis Rheum. 56 (6), 1817–1826.
Takahashi, T., et al., 1999. Ischemia- and cytokine-induced
mobilization of bone marrow-derived endothelial progenitor
cells for neovascularization. Nat. Med. 5 (4), 434–438.
Tepper, O.M., et al., 2002. Human endothelial progenitor cells from
type II diabetics exhibit impaired proliferation, adhesion, and
incorporation into vascular structures. Circulation 106 (22),
2781–2786.
Tepper, O.M., et al., 2005. Adult vasculogenesis occurs through in
situ recruitment, proliferation, and tubulization of circulating
bone marrow-derived cells. Blood 105 (3), 1068–1077.
Vajkoczy, P., et al., 2003. Multistep nature of microvascular
recruitment of ex vivo-expanded embryonic endothelial pro-
genitor cells during tumor angiogenesis. J. Exp. Med. 197 (12),
1755–1765.
Vasa, M., et al., 2001. Number and migratory activity of circulating
endothelial progenitor cells inversely correlate with risk factors
for coronary artery disease. Circ. Res. 89 (1), E1–E7.Wang, S., et al., 2013. CXCR2 macromolecular complex in pancreatic
cancer: a potential therapeutic target in tumor growth. Transl.
Oncol. 6 (2), 216–225.
White, J.R., et al., 1998. Identification of a potent, selective non-
peptide CXCR2 antagonist that inhibits interleukin-8-induced
neutrophil migration. J. Biol. Chem. 273 (17), 10095–10098.
Wu, D., et al., 1993. Identification of critical regions on phospho-
lipase C-beta 1 required for activation by G-proteins. J. Biol.
Chem. 268 (5), 3704–3709.
Wu, Y., et al., 2012. A chemokine receptor CXCR2 macromolecular
complex regulates neutrophil functions in inflammatory dis-
eases. J. Biol. Chem. 287 (8), 5744–5755.
Yeager, M.E., Frid, M.G., Stenmark, K.R., 2011. Progenitor cells in
pulmonary vascular remodeling. Pulm. Circ. 1 (1), 3–16.
Zhou, J., et al., 2013. Rosuvastatin enhances angiogenesis via eNOS-
dependent mobilization of endothelial progenitor cells. PLoS
ONE 8 (5), e63126.
